Skip to content
All resources

GLP-1 and metabolic

Retatrutide Side Effects: What the Clinical Trials Recorded

AM

By

· 9 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 7 sections
  1. How do trials collect and grade side effects?
  2. What did the early trials record?
  3. What did phase 3 record?
  4. Why does heart rate keep coming up?
  5. What can trial safety data not establish?
  6. Is retatrutide approved?
  7. Frequently asked questions

In retatrutide's trials, the most common side effects were gastrointestinal: diarrhoea, nausea, vomiting and constipation, mostly mild to moderate and concentrated during dose escalation. Phase 2 found dose-dependent heart-rate increases that peaked at 24 weeks. In the phase 3 TRIUMPH-2 trial, hypotension and dysesthesia (abnormal skin sensation) were more frequent than on placebo. Permanent discontinuation for adverse events or death reached 12% in one retatrutide arm against 5% on placebo. Retatrutide is investigational and approved nowhere, so its long-term safety record does not yet exist.

A printed adverse event table on a desk beside reading glasses and a pen
Illustration: trial safety data arrive as tables of counted events.

How do trials collect and grade side effects?

Every number below came out of the same machinery, and knowing how it works explains much of what the figures can and cannot say.

Adverse events are not side effects. A trial records every unfavourable medical occurrence after treatment starts, whether or not anyone thinks the drug caused it: a cold, a fracture, a car accident. These are treatment-emergent adverse events. Whether the drug is responsible is inferred by comparing rates with the placebo arm, not by examining individual cases. That is why the placebo column matters as much as the drug column.

They are coded and graded. Investigators record events in their own words, and these are then coded to standard terms, so that "felt sick" and "queasy" both become nausea. Each event is graded for severity, usually mild, moderate or severe. Separately, an event is classed as serious if it results in death, is life-threatening, requires hospital admission, or causes lasting disability. A severe headache can be non-serious, and a mild event that leads to admission is serious.

They are counted in a defined population. Safety analyses usually include everyone who received at least one dose of study drug, as TRIUMPH-2 specified. An event that happens after someone has stopped treatment may or may not be counted, depending on the trial's prespecified rules.

Reporting standards exist because harms were under-reported. The CONSORT extension on harms, published in 2004, added ten recommendations because the original checklist had only one item on safety. Abstracts still report harms less completely than benefits, which matters here: everything below comes from abstracts, and several trials give only "the most common adverse events were gastrointestinal" without rates. For more on how trial design shapes what a result means, see the study design guide.

What did the early trials record?

Phase 1b. Urva and colleagues gave retatrutide, dulaglutide or placebo to 72 people with type 2 diabetes for 12 weeks. Treatment-emergent adverse events were reported by 63% of retatrutide recipients, 60% on dulaglutide and 54% on placebo, with gastrointestinal disorders the most frequent. That more than half the placebo group reported an adverse event is typical and is the reason the comparison column exists. Of the 72 participants, 29 discontinued the study early.

Phase 2 in obesity. In the 338-participant trial reported by Jastreboff and colleagues, gastrointestinal events were dose-related, mostly mild to moderate, and partly reduced when escalation began from a lower level. The trial also reported dose-dependent increases in heart rate that peaked at 24 weeks and declined afterwards. The abstract does not give the size of the increase.

Phase 2 in type 2 diabetes. In Rosenstock and colleagues' 281-participant trial, mild-to-moderate gastrointestinal events occurred in 35% of retatrutide recipients overall, ranging from 13% in the lowest-dose arm to 50% in one of the higher, faster-escalated arms. The rate was 13% on placebo and 35% on dulaglutide, an approved GLP-1 receptor agonist. There was no severe hypoglycaemia and no death.

What did phase 3 record?

TRIUMPH-2, in 1,152 adults with obesity and type 2 diabetes followed for 80 weeks, gives the most detailed published safety picture.

Event in TRIUMPH-2Retatrutide (lowest, middle, highest dose group)Placebo
Diarrhoea27%, 34%, 34%13%
Nausea14%, 21%, 28%8%
Hypotension1%, 5%, 6%under 1%
Dysesthesia4%, 6%, 7%1%
Permanent discontinuation for adverse events or death4%, 12%, 8%5%
Deaths2, 3, 11

Three features deserve attention.

Hypotension and dysesthesia are not the usual incretin story. Gastrointestinal events are expected for anything that acts at the GLP-1 receptor. Low blood pressure and abnormal skin sensation are less familiar, and both rose with dose. The abstract does not say how severe they were, how long they lasted, or whether they resolved. Whether they relate to the glucagon component, to the size of the weight loss, or to something else is not addressed.

Discontinuation did not rise neatly with dose. It peaked at 12% in the middle arm, not the highest. With arms of about 290 people, that may be chance, or it may reflect escalation schemes. The abstract does not explain it.

Deaths were judged unrelated. Six deaths occurred across the retatrutide arms and one on placebo. The investigators judged all of them unrelated to study treatment. The retatrutide arms together held about three times as many people as placebo, which is why counts alone mislead. Individual causality judgements are investigator opinions, and they are one input among several for a regulator.

Other phase 3 reports add less detail. TRANSCEND-T2D-1, in 537 people with type 2 diabetes over 40 weeks, reported mostly mild-to-moderate gastrointestinal events that subsided over time, discontinuation for adverse events of 2% to 5% against 0% on placebo, no severe hypoglycaemia, and two deaths judged unrelated. TRIUMPH-1, in 2,339 adults without diabetes, and the nested sleep apnoea trials state only that gastrointestinal events were the most common. Results by trial are summarised in the retatrutide phase 3 article.

Why does heart rate keep coming up?

Small increases in resting heart rate are recognised across drugs acting at the GLP-1 receptor. Retatrutide adds glucagon-receptor agonism, and glucagon has its own effects on the heart; the receptor guide sets out what each of the three receptors does. The phase 2 finding was that the increase was dose-dependent and peaked at 24 weeks before declining. That is reassuring about the shape, but it does not say whether a sustained increase of any size matters over years. That question belongs to an outcomes trial. TRIUMPH-Outcomes, with an estimated 10,000 participants and a primary completion date listed for 2029, is designed to count cardiovascular events rather than infer them from heart rate.

What can trial safety data not establish?

Rare events. A useful rule of thumb: if an event occurs zero times in a group of a given size, the upper limit of a 95% confidence interval for its rate is about three divided by that size. A few thousand participants on retatrutide can rule out common harms, but not ones affecting one person in several thousand. Pancreatitis, gallbladder disease and rare cancers are the sorts of question that take pooled trials and post-marketing surveillance, as they did for tirzepatide.

Long-term effects. The longest published retatrutide trials run 80 weeks. Effects that need years to appear, or that follow stopping treatment, are outside that window.

Excluded populations. Trials of this kind typically screen out people with conditions such as a history of pancreatitis, pregnancy or advanced organ disease. TRIUMPH-2, for example, required diabetes to be on stable treatment before enrolment. The results describe the people enrolled.

Anything about product outside a trial. Trial safety data describe Lilly's characterised investigational product, given under monitoring. Published case reports of people using product sold as retatrutide outside trials are covered in gray-market retatrutide and the evidence. They cannot be combined with trial data, because nobody knows what those vials contained.

Is retatrutide approved?

No. No regulator, including Health Canada and the US Food and Drug Administration, has approved retatrutide for any use. Authorised drugs in Canada carry a Drug Identification Number listed in the Drug Product Database. The retatrutide overview covers its pharmacology and the rest of its trial programme.

Supplied here for laboratory use: Retatrutide. The laboratory's certificate for each lot is linked from its product page. For laboratory research use only.

The safety findings on this page describe trial participants given the investigational drug. They are not evidence about any laboratory reagent. Nothing here is medical, dosing, or therapeutic guidance.

Frequently asked questions

What is the most common side effect of retatrutide? In every published trial, gastrointestinal events were the most common: diarrhoea, nausea, vomiting and constipation. In TRIUMPH-2, diarrhoea affected 27% to 34% of retatrutide recipients against 13% on placebo, and nausea 14% to 28% against 8%. Most were mild to moderate and occurred during dose escalation.

Does retatrutide raise heart rate? The phase 2 obesity trial reported dose-dependent increases in heart rate that peaked at 24 weeks and then declined. The abstract does not give the size of the increase. Whether a sustained rise matters clinically over years is unknown, and TRIUMPH-Outcomes is the trial designed to measure cardiovascular events directly.

What is dysesthesia, and why was it reported? Dysesthesia is an abnormal, often unpleasant skin sensation such as tingling, burning or sensitivity to touch. In TRIUMPH-2 it occurred in 4% to 7% of retatrutide recipients against 1% on placebo. The abstract does not describe severity, duration or mechanism, so its significance is an open question.

How many people stopped retatrutide because of side effects? In TRIUMPH-2, permanent discontinuation for adverse events or death was 4%, 12% and 8% across the three retatrutide arms, against 5% on placebo. In TRANSCEND-T2D-1, discontinuation for adverse events was 2% to 5% against 0%. The figures are not comparable across trials with different populations.

Are there long-term safety data for retatrutide? Not yet. Published trials last up to 80 weeks and enrol screened volunteers. Rare harms, effects after stopping and cardiovascular outcomes need larger and longer studies, including TRIUMPH-Outcomes, which ClinicalTrials.gov lists with a primary completion date in 2029. Until then, the safety record is the one described on this page.

Selected Research References

  1. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet. 2022;400(10366):1869-1881. pubmed.ncbi.nlm.nih.gov/36354040
  2. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. pubmed.ncbi.nlm.nih.gov/37366315
  3. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet. 2023;402(10401):529-544. pubmed.ncbi.nlm.nih.gov/37385280
  4. Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet. 2026;408(10563):1455-1472. pubmed.ncbi.nlm.nih.gov/42810372
  5. Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. The Lancet. 2026;407(10546):2402-2413. pubmed.ncbi.nlm.nih.gov/42250575
  6. Jastreboff AM, Kaplan LM, Davies MJ, et al.; TRIUMPH-1 Investigators. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. 2026. pubmed.ncbi.nlm.nih.gov/42814954
  7. Ioannidis JP, Evans SJ, Gøtzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine. 2004;141(10):781-788. pubmed.ncbi.nlm.nih.gov/15545678

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.